VPC-70063

Cat. No.:	HY-147291
CAS No.:	13571-44-3
Molecular Formula:	$C_{16}H_{12}F_6N_2S$
Molecular Weight:	378.34
Target:	c-Myc; PARP; Apoptosis
Pathway:	Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	VPC-70063 is a potent Myc-Max inhibitor with an IC_{50} value of 8.9 μM for Myc-Max transcriptional activity inhibition. VPC-70063 reduces UBE2C promotor activity and AR-V7 levels, and induces PARP cleavage. VPC-70063 induces apoptosis and blocks Myc-Max interactions with DNA. VPC-70063 can be used for researching anticancer[1].
IC_{50} & Target	IC_{50}: 8.9 μM (Myc-Max)[1]
In Vitro	VPC-70063 (25 μM; 96 h) shows Myc-Max transcriptional activity inhibition of 106% and Myc-Max/UBE2C downstream pathway inhibition of 94%[1]. VPC-70063 (6.25-25 μM, 48 h) causes apoptosis of LNCaP cells as indicated by cleavage of PARP[1]. VPC-70063 (0-500 μM; 0-600 s) disrupts the interaction of Myc-Max with DNA in a dose dependent manner[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	LNCaP cells
Concentration:	6.25 μM, 12.5 μM and 25 μM
Incubation Time:	48 h
Result:	Induced PARP cleavage.

REFERENCES

[1]. Carabet LA, et al. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. Eur J Med Chem. 2018 Dec 5;160:108-119.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA